PMID- 23587015
OWN - NLM
STAT- MEDLINE
DCOM- 20130701
LR  - 20221207
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 11
DP  - 2013 Apr 12
TI  - Minimal clinically important differences for the EQ-5D and QWB-SA in 
      Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized 
      Preference Trial (DRPT).
PG  - 59
LID - 10.1186/1477-7525-11-59 [doi]
AB  - OBJECTIVE: To determine the minimal clinically important difference (MCID) for 
      the health-utility measures EuroQol-5 dimensions (EQ-5D) and Quality of Well 
      Being Self-Administered (QWB-SA) Scale in PTSD patients. RESEARCH DESIGN AND 
      METHODS: Two hundred patients aged 18 to 65 years with PTSD enrolled in a doubly 
      randomized preference trial (DRPT) examining the treatment and 
      treatment-preference effects between cognitive behavioral therapy and 
      pharmacotherapy with sertraline and completed the EQ-5D and QWB-SA at baseline 
      and 10-week post-treatment. The anchor-based methods utilized a Clinical Global 
      Impression-Improvement (CGI-I) and Clinical Global Impression-Severity. We 
      regressed the changes in EQ-5D and QWB-SA scores on changes in the anchors using 
      ordinary least squares regression. The slopes (beta coefficients) were the rates 
      of change in the anchors as functions of change in EQ-5D and QWB, which represent 
      our estimates of MCID. In addition, we performed receiver operating 
      characteristic (ROC) curve analysis to examine the relationship between the 
      changes in EQ-5D and QWB-SA scores and treatment-response status. The MCIDs were 
      estimated from the ROC curve where they best discriminate between treatment 
      responders and non-responders. The distribution-based methods used small to 
      moderate effect size in terms of 0.2 and 0.5 of standard deviation of the 
      pre-treatment EQ-5D and QWB-SA scores. RESULTS: The anchor-based methods 
      estimated the MCID ranges of 0.05 to 0.08 for the EQ-5D and 0.03 to 0.05 for the 
      QWB. The MCID ranges were higher with the distribution-based methods, ranging 
      from 0.04 to 0.10 for the EQ-5D and 0.02 to 0.05 for the QWB-SA. CONCLUSIONS: The 
      established MCID ranges of EQ-5D and QWB-SA can be a useful tool in assessing 
      meaningful changes in patient's quality of life for researchers and clinicians, 
      and assisting health-policy makers to make informing decision in mental health 
      treatment. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov; Identifier: 
      NCT00127673.
FAU - Le, Quang A
AU  - Le QA
AD  - Department of Pharmacy Administration and Practice, Western University of Health 
      Sciences, Pomona, CA 91766-1854, USA. qle@westernu.edu
FAU - Doctor, Jason N
AU  - Doctor JN
FAU - Zoellner, Lori A
AU  - Zoellner LA
FAU - Feeny, Norah C
AU  - Feeny NC
LA  - eng
SI  - ClinicalTrials.gov/NCT00127673
GR  - R01 MH066347/MH/NIMH NIH HHS/United States
GR  - R01 MH066348/MH/NIMH NIH HHS/United States
GR  - R01MH066348/MH/NIMH NIH HHS/United States
GR  - R01MH066347/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20130412
PL  - England
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Cognitive Behavioral Therapy
MH  - Epilepsy, Post-Traumatic/drug therapy/*psychology
MH  - Female
MH  - Health Status Indicators
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Preference
MH  - *Psychiatric Status Rating Scales
MH  - ROC Curve
MH  - Regression Analysis
MH  - Research Design
MH  - Selective Serotonin Reuptake Inhibitors/therapeutic use
MH  - Sertraline/therapeutic use
MH  - Severity of Illness Index
MH  - *Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC3635945
EDAT- 2013/04/17 06:00
MHDA- 2013/07/03 06:00
PMCR- 2013/04/12
CRDT- 2013/04/17 06:00
PHST- 2012/11/13 00:00 [received]
PHST- 2013/03/26 00:00 [accepted]
PHST- 2013/04/17 06:00 [entrez]
PHST- 2013/04/17 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
PHST- 2013/04/12 00:00 [pmc-release]
AID - 1477-7525-11-59 [pii]
AID - 10.1186/1477-7525-11-59 [doi]
PST - epublish
SO  - Health Qual Life Outcomes. 2013 Apr 12;11:59. doi: 10.1186/1477-7525-11-59.